GNTA vs. MGX, ZURA, IPHA, ELEV, GLUE, IVVD, CHRS, SCLX, CMPX, and FENC
Should you be buying Genenta Science stock or one of its competitors? The main competitors of Genenta Science include Metagenomi (MGX), Zura Bio (ZURA), Innate Pharma (IPHA), Elevation Oncology (ELEV), Monte Rosa Therapeutics (GLUE), Invivyd (IVVD), Coherus BioSciences (CHRS), Scilex (SCLX), Compass Therapeutics (CMPX), and Fennec Pharmaceuticals (FENC). These companies are all part of the "biological products, except diagnostic" industry.
Metagenomi (NASDAQ:MGX) and Genenta Science (NASDAQ:GNTA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk.
Metagenomi received 3 more outperform votes than Genenta Science when rated by MarketBeat users. Likewise, 90.00% of users gave Metagenomi an outperform vote while only 85.71% of users gave Genenta Science an outperform vote.
Genenta Science has lower revenue, but higher earnings than Metagenomi.
In the previous week, Metagenomi and Metagenomi both had 3 articles in the media. Metagenomi's average media sentiment score of 0.96 beat Genenta Science's score of 0.72 indicating that Genenta Science is being referred to more favorably in the news media.
15.1% of Genenta Science shares are held by institutional investors. 29.0% of Genenta Science shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Metagenomi presently has a consensus target price of $17.83, indicating a potential upside of 179.52%. Genenta Science has a consensus target price of $25.00, indicating a potential upside of 683.70%. Given Metagenomi's stronger consensus rating and higher probable upside, analysts clearly believe Genenta Science is more favorable than Metagenomi.
Summary
Genenta Science beats Metagenomi on 6 of the 10 factors compared between the two stocks.
Get Genenta Science News Delivered to You Automatically
Sign up to receive the latest news and ratings for GNTA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GNTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Genenta Science Competitors List
Related Companies and Tools
